Editor’s Note: The following was written on behalf of the Diagnostic Working Group of the IASLC Early Detection & Screening Committee.
Low-dose CT (LDCT) screening has transformed outcomes for lung cancer (LC), in which late-stage diagnosis has historically made cure an exception rather than the norm. Landmark studies have demonstrated that CT-detected stage I LC carries an estimated 20-year LC-specific survival of 80%,1 in stark contrast to the outcomes in symptom-driven diagnosis. Multiple randomized controlled trials have confirmed that screening reduces LC mortality in defined high-risk populations.2,3
As programs mature globally, it is increasingly clear that the central question is no longer whether screening works, but rather who should have access and how societies choose to deploy it. Current eligibility criteria, primarily defined by smoking history and age, capture only a fraction of individuals who develop LC,4 reflecting policy decisions shaped by economics and resource allocation rather than biological judgments about who can benefit from early detection.
Current Screening Eligibility Criteria Are Not Fully Inclusive

A substantial proportion of LC cases arise in individuals whose risk profiles fall outside existing guidelines. These include people who never smoked, as well as individuals with lighter smoking history or longer quit times. It also includes individuals with risks such as occupational exposures, air pollution, radon, prior lung disease, and family history. In many regions of the world, these groups—including Indigenous peoples, who are amongst those with the highest global LC burden yet remain least represented in trials from which eligibility criteria are derived—account for a growing share of LCs.5,6
An underappreciated fact is that once LC is present, it behaves similarly regardless of the individual’s risk profile.7 The current staging system makes no distinction based on smoking status, pollution exposure, or occupational risk. A stage I LC in a person who never smoked is currently treated the same way with the same potential for cure as the same diagnosis and stage in a person with a heavy smoking history.8
Identifying Additional Individuals Within the Current Risk Categories
Extending to lower risk individuals requires additional consideration. In low-risk cohorts, more people must be screened to identify cancers, resulting in increased workload and potential for unnecessary and invasive diagnostic evaluations in individuals who may never develop LC. Severe comorbid conditions limiting life expectancy increase the risk of LC treatment and reduce the screening benefit. These are legitimate societal and economic considerations, but they do not negate the fact that the individual whose cancer is found early benefits from its detection. The key question is how many must be screened to identify the individual who stands to benefit, at what cost to society, and with how much potential harm.
It is equally important to recognize that the harm side of this equation has shifted considerably since the early screening trials. Concerns such as false-positive rates, unnecessary invasive procedures, and radiation exposure have steadily declined as protocols have matured.9
Conservative nodule management strategies, volumetric growth assessment, extended follow-up and screening intervals, dramatically lower radiation doses, bronchoscopic advances, and minimally invasive surgery have fundamentally altered the risk-benefit calculus.10 The evidence base for harm must therefore be interpreted in the context of contemporary screening practice, not historical benchmarks.
Data-Driven Expansion of Risk Factors

Part of the solution is to improve risk stratification so that individuals who have a comparable probability of developing LC can be offered LCS. Rather than anchoring expansion to the populations enrolled in early randomized trials, eligibility should evolve in line with contemporary epidemiology, real-world data, and locally relevant risk factors, while keeping the individual benefit of detecting curable cancer at the center of decision-making.
This is especially important in Asian settings, where risk assessment may need to incorporate non-smoking determinants such as outdoor air pollution, household cooking fumes, second-hand tobacco smoke exposure, and genetic susceptibility.11,12,13 Eligibility frameworks should be flexible enough to reflect local epidemiology and implementation context.
A principled epidemiological framework is essential to this effort. The relevant question is not whether a population-level trial demonstrates net benefit across all comers, but whether the individual whose cancer is detected early benefits and what risk threshold justifies the societal investment required to find them. This framing shifts the evaluation from asking whether screening demonstrates benefit in a population-level trial to balancing individual benefit against population-level feasibility. These are distinct questions with different policy implications.
Two groups warrant particular attention. Women who have never smoked, particularly of Asian origin, represent a growing proportion of LC cases, driven by distinct biological and exposure profiles which are poorly captured in current criteria.14 Specific occupational exposures such as asbestos, silica, diesel exhaust, and other carcinogens also carry elevated risks not addressed by current guidelines.15 The full landscape of relevant exposures, industrial pollutants, ambient air pollution, radon, and regional environmental factors remains incompletely characterized in most screening frameworks,13,16 representing a significant yet addressable knowledge gap.
Equity considerations further complicate the application of rigid eligibility thresholds. In many regions of the world, exposure histories are poorly documented, air quality monitoring is limited, and occupational risks go unrecorded. In some regions, Indigenous peoples face this gap acutely: tobacco use, exposures on traditional lands, geographic remoteness, and historical systemic disadvantages combine into LC risks that formal eligibility criteria rarely capture.6 Individuals in these settings may carry substantial risk without the means to demonstrate it, excluding the very populations most exposed to environmental and occupational harm. Appropriate science-driven advocacy is essential to ensure that screening access reflects the local LC burden rather than coverage exercise.
It is also important to reconsider how eligibility decisions are communicated to individuals who do not meet current eligibility criteria. Imprecise language can contribute to misinformation: terms such as ‘harm,’ ‘false positive,’ or ‘radiation risk’ are often interpreted without context; they can magnify perceived harms and obscure contemporary screening practice reductions.17,18
Telling a person with a light smoking history or a shorter exposure history that screening is “not beneficial” oversimplifies a complex reality. The issue is not primarily lack of benefit; rather, screening access at low-risk thresholds has not been prioritized within cost-constraint frameworks. Having authentic shared decision-making conversations rises to the level of ethical obligation and matters of public trust, particularly for historically marginalized communities where culturally safe outreach is essential.19
Improving Detection and Handling of Incidental Pulmonary Nodules

An underutilized pathway to early LC detection existing within current clinical practice is systematic management of incidentally detected pulmonary nodules (IPN). These nodules arise during chest imaging performed for indications unrelated to screening.
Hundreds of thousands of patients with IPN are identified globally each year,20,21 with LC prevalence quite high in this cohort.22 IPNs should be evaluated. If cancer is diagnosed, it should be treated. The clinical imperative is identical to that in screen-detected cases.
The only difference between incidental detection of a pulmonary nodule and a nodule detected through organized screening is whether society chooses to consequently investigate the nodule further. This is not just a matter of cost but also a matter of time given the current speed of healthcare delivery, particularly within the setting of emergency departments.20,21
Structured programs for follow-up and management of incidental nodules extend the reach of early detection to individuals whose risk profiles fall outside eligibility criteria, and available evidence suggests individual benefit is comparable.23 Strengthening these programs through standardized protocols, automated tracking systems, dedicated follow-up infrastructure, and integration with existing radiology workflows represents an actionable strategy for expanding early detection independent of eligibility criteria.
Improving Currently Available Options

Before eligibility is broadened to include additional risk factors, the full potential of existing programs must be realized. Participation rates remain suboptimal, and adherence to recommended follow-up intervals is inconsistent,24,25 both representing lost opportunities for eligible individuals.
Tobacco cessation is a key component of high-quality LC screening programs. It doubles the benefits of screening26 and must be discussed with all concerned participants who continue to smoke cigarettes or have other tobacco exposures.27 LC screening visits create a powerful, evidence‑based “teachable moment” during which screenees should receive proactive, structured cessation assessment, counseling, and access to effective pharmacologic and behavioral support.
Finally, LC screening no longer functions in isolation as a single-disease intervention, but increasingly as a comprehensive preventive assessment. Emerging evidence supports the clinical value of information captured incidentally during a single scan, such as coronary artery calcification,28 emphysema severity,29 and vertebral bone density30—conditions that together account for substantially greater morbidity and mortality than LC alone. As evidence accumulates for the value of these findings, the calculus of screening shifts from a single-disease intervention toward comprehensive preventive assessment.31
Conclusions
Smoking- and age-based eligibility criteria do not adequately identify all individuals who stand to benefit from early LC detection, a limitation that is particularly consequential in regions and populations where genetics, environmental exposures, and occupational hazards play a significant role. Before pursuing lower-risk populations, the priority should be to improve risk stratification to include individuals with comparable risk who are outside current guidelines but who would benefit from LC screening.
In the meantime, improving participation in existing programs, strengthening the management of incidentally detected pulmonary nodules, and pursuing rigorous data-driven advocacy toward expanding screening access to underserved, high-risk populations represent the most immediate and impactful steps toward achieving more equitable access to early detection of LC.
Members of the Diagnostics Working Group of the IASLC Early Detection and Screening Committee
| Haval Balata | Andrea Borondy Kitts |
| Milena Čavić | John K. Field |
| Kwun M. Fong | Anne Fraser |
| So Yeon Kim | Marjolein Heuvelmans |
| Stephen Lam | Claudia Henschke |
| Rudolf Huber | Rosemary Innih |
| Long Jiang | Artit Jirapatnakul |
| Ella Kazerooni | Anne Kerpel-Fronius |
| David C.L. Lam | Rafael Meza |
| Anant Mohan | Theresa Roelke |
| Antoni Rosell | Witold Rzyman |
| Jacob Sands | Ricardo Santos |
| Dorith Shaham | Junichi Soh |
| Kevin ten Haaf | Martin Tammemägi |
| Betty Tong | Natthaya Triphuridet |
| Luigi Ventura | Lucia Viola |
| Dawei Yang | Rozemarijn Vliegenthart |
| Rowena Yip | David Yankelevitz |
References
- 1. Henschke CI, Yip R, Shaham D, et al. A 20-year Follow-up of the International Early Lung Cancer Action Program (I-ELCAP). Radiology 2023;309:e231988.
- 2. Aberle D, Adams A, Berg C, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. The New England journal of medicine 2011;365:395–409.
- 3. de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. The New England journal of medicine 2020;382:503–513.
- 4. Yang HC, Chang A, Visa M, et al. Age-Based Screening for Lung Cancer Surveillance in the US. JAMA Network Open 2025;8:e2546222.
- 5. Kerpel-Fronius A, Tammemägi M, Cavic M, et al. Screening for Lung Cancer in Individuals Who Never Smoked: An International Association for the Study of Lung Cancer Early Detection and Screening Committee Report. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 2022;17:56–66.
- 6. Belachew SA, Bizuayehu HM, Diaz A, et al. Lung Cancer Screening Participation Among Indigenous Peoples Worldwide: A Systematic Review of Challenges and Opportunities. Health Promot J Austr 2025;36:e70001.
- 7. Adler S, Yip R, Chan H, et al. Comparison of lung cancer aggressiveness in patients who never smoked compared to those who smoked. Lung Cancer (Amsterdam, Netherlands) 2022;171:90–96.
- 8. Li CC, Matthews AK, Rywant MM, et al. Racial disparities in eligibility for low-dose computed tomography lung cancer screening among older adults with a history of smoking. Cancer causes & control : CCC 2019;30:235–240.
- 9. Christensen J, Prosper AE, Wu CC, et al. ACR Lung-RADS v2022: assessment categories and management recommendations. J Am Coll Radiol 2024;21:473–488.
- 10. Vonder M, Dorrius MD, Vliegenthart R. Latest CT technologies in lung cancer screening: protocols and radiation dose reduction. Transl Lung Cancer Res 2021;10:1154–1164.
- 11. Myers R, Brauer M, Dummer T, et al. High-Ambient Air Pollution Exposure Among Never Smokers Versus Ever Smokers With Lung Cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer 2021;16:1850–1858.
- 12. Chu X, Wang Q, Su C. Indoor air pollution: An important risk factor for lung cancer among Asian women without a history of smoking. Chin Med J Pulm Crit Care Med 2023;1:198–199.
- 13. Berg CD, Schiller JH, Boffetta P, et al. Air Pollution and Lung Cancer: A Review by International Association for the Study of Lung Cancer Early Detection and Screening Committee. Journal of Thoracic Oncology: official publication of the International Association for the Study of Lung Cancer 2023;18:1277–1289.
- 14. Yang C-Y, Lin Y-T, Lin L-J, et al. Stage Shift Improves Lung Cancer Survival: Real-World Evidence. Journal of Thoracic Oncology 2023;18:47–56.
- 15. Markowitz S, Ringen K, Dement JM, et al. Occupational lung cancer screening: A Collegium Ramazzini statement. American journal of industrial medicine 2024;67:289–303.
- 16. Arrieta O, Arroyo-Hernández M, Soberanis-Piña PD, et al. Facing an unmet need in lung cancer screening: The never smokers. Crit Rev Oncol Hematol 2024;202:104436.
- 17. Tupper HI, Shrager JB, Moghanaki D, et al. Misinformation and Overestimation of Computed Tomography Lung Cancer Screening Harms—Methodology Matters: A Joint Statement from The Society of Thoracic Surgeons, the American Society for Radiation Oncology, and the American College of Radiology. The Annals of Thoracic Surgery 2026;121:544–547.
- 18. Yankelevitz DF. CT Screening for Lung Cancer: Successful Trial, but Failed Understanding. Journal of Thoracic Oncology 2018;13:12–15.
- 19. Tsosie U, Anderson N, Woo N, et al. Understanding determinants of lung cancer preventive care in at-risk urban American Indians and Alaska Natives: A mixed-methods study. Preventive Medicine Reports 2024;45:102822.
- 20. Mazzone PJ, Lam L. Evaluating the Patient With a Pulmonary Nodule: A Review. JAMA: The Journal of the American Medical Association 2022;327:264–273.
- 21. Das A, Bonney A, Manser R. Prevalence of pulmonary nodules detected incidentally on noncancer-related imaging: a review. Intern Med J 2024;54:1440–1449.
- 22. Osarogiagbon RU, Liao W, Faris NR, et al. Lung cancer diagnosed through screening, lung nodule, and neither program: a prospective observational study of the detecting early lung cancer (DELUGE) in the Mississippi delta cohort. Journal of Clinical Oncology 2022;40:2094.
- 23. MacMahon H, Naidich DP, Goo JM, et al. Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. Radiology 2017:161659.
- 24. Ezenwankwo E, Yell N, Eberth JM. Lung Cancer Screening in the United States, 2024: A National Health Interview Survey Analysis. Chest 2026;169:1148–1153.
- 25. Smith HB, Schneider E, Tanner NT. An Evaluation of Annual Adherence to Lung Cancer Screening in a Large National Cohort. Am J Prev Med 2022;63:e59–e64.
- 26. Tanner NT, Kanodra NM, Gebregziabher M, et al. The Association between Smoking Abstinence and Mortality in the National Lung Screening Trial. American journal of respiratory and critical care medicine 2016;193:534–541.
- 27. Williams PJ, Philip KE, Alghamdi SM, et al. Strategies to deliver smoking cessation interventions during targeted lung health screening – a systematic review and meta-analysis. Chron Respir Dis 2023;20:14799731231183446.
- 28. Shemesh J, Yip R, Cham M, et al. ELCAP Coronary Artery Calcium Score at Lung Cancer Screening CT Predicts Up to 25-Year Mortality. Radiology 2025;316:e250090.
- 29. González Gutiérrez J, Yip R, Zulueta JJ, et al. Emphysema at Baseline Low-Dose CT Lung Cancer Screening Predicts Death from Chronic Obstructive Pulmonary Disease and Cardiovascular Disease Up to 25 Years Later. Radiology 2025;316:e250949.
- 30. Zhu Y, Yip R, Jirapatnakul AC, et al. Visual scoring of osteoporosis on low-dose CT in lung cancer screening population. Clinical Imaging 2024;109:110115.
- 31. Mulshine JL, Pyenson B, Healton C, et al. Paradigm shift in early detection: Lung cancer screening to comprehensive CT screening. European Journal of Cancer 2025;218:115264.
